title: Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
authors.affiliation: Department of Gastroenterology, Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Barreiro-de Acosta
authors.affiliation: Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
authors.forename: J P
authors.identifier: 0000-0003-2090-3445
authors.initials: JP
authors.lastname: Gisbert
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001315:Australia; D003424:Crohn Disease; D006801:Humans; D000069285:Infliximab; D009520:New Zealand
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab